End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
0.4272 USD | -3.87% | +6.37% | -12.30% |
30/04 | Akili, Inc. Plans to Continue to Pursue Marketing Authorization from the U.S. Food and Drug Administration for Its EndeavorOTC Product | CI |
30/04 | Akili, Inc. to Reduce Workforce | CI |
Evolution of the average Target Price on Akili, Inc.
Price target over the last 5 years
History of analyst recommendation changes
Analysts' Consensus
Consensus detail
Consensus revision (last 18 months)
Analysts covering Akili, Inc.
Morgan Stanley | |
BofA Securities | |
Credit Suisse | |
Cowen |
- Stock Market
- Equities
- AKLI Stock
- Consensus Akili, Inc.